Bifidobacterium breve capable of relieving rheumatoid arthritis and application thereof
US12285448B2 · kind B2 · utility
Inventors
Key dates
| Filing date | Mar 17, 2022 |
| Grant date | Apr 29, 2025 |
| Priority date | — |
| Expiry date | Jul 28, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA23V2400/519
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described is a B. breve strain for relieving rheumatoid arthritis and application thereof, belonging to the technical field of microorganisms. Described is a B. breve strain CCFM1078 possessing the effect of relieving rheumatoid arthritis, and shown to: promote secretion of anti-inflammatory factor IL-10 from RAW264.7 cells; reduce joint thickness, clinical score, and incidence of rats with rheumatoid arthritis; decrease levels of the pro-inflammatory cytokines TNFα and IL-1β in the serum of rats with rheumatoid arthritis; regulate the content of short-chain fatty acids in the feces of rats with rheumatoid arthritis; decrease the proportion of Th17 cells in the mesenteric lymph nodes of rats with rheumatoid arthritis; and reduce secretion of pro-inflammatory factor IL-6 from synovial cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.